Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: AstraZeneca AB, SE-151 85 Södertälje, Sweden
Lynparza 50 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. White, opaque, size 0 hard capsule, marked with “OLAPARIB 50 mg” and the AstraZeneca logo in black ink. |
Each hard capsule contains 50 mg of olaparib.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Olaparib |
Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2, and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies or new hormonal agents (NHA). |
| List of Excipients |
|---|
|
Capsule content: Lauroyl macrogol-32 glycerides Capsule shell: Hypromellose Printing ink: Shellac |
HDPE plastic bottle with a child-resistant closure containing 112 hard capsules.
Pack of 448 capsules (4 bottles of 112 capsules).
AstraZeneca AB, SE-151 85 Södertälje, Sweden
EU/1/14/959/001
Date of first authorisation: 16 December 2014
| Drug | Countries | |
|---|---|---|
| LYNPARZA | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
